Theresa Heggie

Scientific Advisor at ProQR Therapeutics

Theresa Heggie was reappointed to ProQR’s Supervisory Board in 2023. Previously, Ms. Heggie served as the Chief Operating Officer at ProQR, after originally joining the Management Team in 2021 as the Chief Commercial Officer. Prior to ProQR, she served as Chief Executive Officer of Freeline Therapeutics. She had senior commercial and operating roles at Alnylam Pharmaceuticals as Senior Vice President, Head of CEMEA and Shire where she built the EMEA rare disease business. Earlier in her career, Ms. Heggie held increasingly senior positions in the commercial organizations at Janssen Pharmaceuticals and Baxter Healthcare. She previously served on the ProQR Supervisory Board from 2019-2021.

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


ProQR Therapeutics

1 followers

ProQR Therapeutics develops RNA therapies to potentially transform the lives of patients suffering from inherited retinal diseases.


Industries

Employees

51-200

Links